.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of people along with HER2+ state-of-the-art breast cancer and energetic or stable brain metastases presented steady intracranial task as well as wide spread effectiveness of T-DXd.